News: Brokerage

Roche inaugurates Translational and Clinical Research Center at the Alexandria Center for Life Science in New York City

Roche and Alexandria Real Estate Equities, Inc. have inaugurated the Translational and Clinical Research Center (TCRC) at the Alexandria Center for Life Science at the East Side Medical Corridor by hosting New York officials and dignitaries as well as life science leaders from institutions across the U.S. The Roche TCRC is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center's importance to pRED and Roche. The TCRC staff is comprised of some 250 highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche's existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules. The Roche TCRC staff will officially move into the Alexandria Center for Life Science on January 2, 2014. "We are pleased to have the TCRC based at the Alexandria Center for Life Science and excited by the collaborative opportunities afforded by its proximity to patients and world-class expertise in experimental medicine," said John Reed, MD, PhD, Head of Roche Pharma Research and Early Development. "New York City has much to offer - it is the most populated city in America, has seven outstanding medical schools and also ranks second in the U.S. in medical research funding (NIH). Therefore, we believe this is the best location to pursue the goals of the TCRC as well as our global research and development organization." "We are honored that Roche has chosen the Alexandria Center for Life Science as the home for its Translational and Clinical Research Center," said Joel Marcus, chairman, CEO and founder of Alexandria Real Estate Equities, Inc. "New York City has an unparalleled concentration of world-class academic medical research centers and is the ideal platform for Roche to substantially enhance its collaboration and translational clinical efforts." "TCRC will serve as an important conduit between the life sciences community in North America and the global Roche organization," said Judith Dunn, PhD, head of the Roche TCRC. "Our location in the Alexandria Center for Life Science will enable us to combine our expertise with that of world class researchers here in a vibrant scientific environment. We will be engaging collaborators in a transformative approach to drug development, which will provide solutions for unmet medical needs and ultimately improve the lives of patients and their families." Following the inauguration ceremony, Roche hosted a scientific symposium with an impressive line-up of keynote speakers who discussed advances in key areas of research being conducted by pRED. The areas of oncology, neuroscience, diabetic complications and infectious diseases were featured, with particular emphasis on acute myeloid leukemia, spinal muscular atrophy, diabetic kidney disease and influenza. During the symposium, Roche also presented TCRC Young Investigator Awards to four promising researchers: Carolina Bigarella, PhD, Mount Sinai School of Medicine for cancer research; Christian Simon, PhD, Columbia University for neurology research; Alexander Grabner, MD, University of Miami Miller School of Medicine for diabetes research; and Priya Luthra, PhD, Mount Sinai School of Medicine for infectious diseases research. Roche encouraged applications from researchers who have completed their graduate degrees (MD and/or PhD) within the past five years and who are studying disease areas of interest to Roche. Grants were awarded to the four institutions that employ the researchers.
MORE FROM Brokerage

AmTrustRE secures 5,754 s/f lease with GKV Architects at 360 Lexington Avenue

Manhattan, NY AmTrustRE has executed a 5,754 s/f lease at its premier boutique Midtown East office tower, 360 Lexington Ave., with longtime partner GKV Architects. The award-winning firm will occupy a portion of the 14th floor. >“GKV Architects has been a trusted partner to AmTrustRE for over two decades, playing an integral role in shaping and elevating several
READ ON THE GO
DIGITAL EDITIONS
Subscribe
Columns and Thought Leadership
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
A fresh start - by Shallini Mehra and Amit Doshi

A fresh start - by Shallini Mehra and Amit Doshi

For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced
Tri-state capital  migrates nationally amid  regulation pressure - by Reese Weaver

Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver

New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,